JMP Securities Reaffirms “Market Outperform” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “market outperform” rating restated by JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. JMP Securities’ price objective indicates a potential upside of 126.24% from the company’s current price.

TSHA has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Canaccord Genuity Group cut their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $6.38.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $2.21 on Tuesday. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The firm has a market capitalization of $452.92 million, a PE ratio of -11.15 and a beta of 0.44. The business’s 50 day moving average is $1.97 and its 200-day moving average is $2.39. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $3.62 million. During the same quarter in the previous year, the company posted ($0.38) EPS. Sell-side analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors have recently made changes to their positions in the stock. MetLife Investment Management LLC raised its position in Taysha Gene Therapies by 81.9% in the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock valued at $153,000 after purchasing an additional 34,243 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Taysha Gene Therapies by 7.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock valued at $930,000 after buying an additional 33,123 shares during the period. Intech Investment Management LLC acquired a new position in Taysha Gene Therapies in the 3rd quarter valued at $85,000. GSA Capital Partners LLP increased its stake in Taysha Gene Therapies by 64.7% in the 3rd quarter. GSA Capital Partners LLP now owns 233,560 shares of the company’s stock valued at $469,000 after buying an additional 91,755 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in Taysha Gene Therapies in the 3rd quarter valued at $416,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.